Exciting research publication from our cardiology lab SYNCROSOME as co-author
Cardiovascular diseases (CVDs) are the leading cause of global mortality. That’s why we are proud to share a groundbreaking study titled « Urolithin A provides cardioprotection and mitochondrial quality enhancement preclinically and improves human cardiovascular health biomarkers« . Liu, Sophia et al. iScience, Volume 28, Issue 2, 111814
This study highlights the potential of Urolithin A (UA), a post-biotic and mitophagy activator, to improve heart health by addressing mitochondrial dysfunctions. Preclinical model results show reduced cardiac dysfunction, while human trials indicate significant reductions in plasma ceramides, making UA a promising nutritional intervention for aging populations !
And hope for patients with Cardiovascular diseases.
